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Background: Human pluripotent stem cells (hPSCs) hold great promise for applications in regenerative medicine.
However, the safety of cell therapy using differentiated hPSC derivatives must be improved through methods that
will permit the transplantation of homogenous populations of a specific cell type. To date, purification of
progenitors and mature cells generated from either embryonic or induced pluripotent stem cells remains
challenging with use of conventional methods.
Results: We used lentivectors encoding green fluorescent protein (GFP) driven by the liver-specific apoliprotein A-II
(APOA-II) promoter to purify human hepatic progenitors. We evaluated both integrating and integration-defective
lentivectors in combination with an HIV integrase inhibitor. A human embryonic stem cell line was differentiated
into hepatic progenitors using a chemically defined protocol. Subsequently, cells were transduced and sorted at
day 16 of differentiation to obtain a cell population enriched in hepatic progenitor cells. After sorting, more than
99% of these APOA-II-GFP-positive cells expressed hepatoblast markers such as α-fetoprotein and cytokeratin 19.
When further cultured for 16 days, these cells underwent differentiation into more mature cells and exhibited
hepatocyte properties such as albumin secretion. Moreover, they were devoid of vector DNA integration.
Conclusions: We have developed an effective strategy to purify human hepatic cells from cultures of differentiating
hPSCs, producing a novel tool that could be used not only for cell therapy but also for in vitro applications such as
drug screening. The present strategy should also be suitable for the purification of a broad range of cell types
derived from either pluripotent or adult stem cells.
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Cell therapy is now a viable alternative to liver trans-
plantation for the treatment of chronic liver diseases.
However, this approach is limited by the shortage of re-
producible sources of human hepatocytes [1]. Human
pluripotent stem cells (hPSCs) are an ideal source for
generating hepatocytes because they can be isolated,* Correspondence: anne.dubart@inserm.fr
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reproduction in any medium, provided the orexpanded as clonal populations to generate sufficient
numbers, and differentiated in vitro. Human embryonic
stem cells (hESCs) remain the most reliable option, as
they display an unlimited capacity for self-renewal.
We and others have generated hepatocyte-like cells
from hESCs in animal-free conditions by recapitulating
liver developmental stages [2-7]. However, although
these differentiation protocols are relatively efficient, the
presence of cells of an undesirable phenotype might pose
health risks in the context of cell transplantation. Hence,
for clinical applications, it is essential to transplant
homogenous cell preparations that are highly enrichedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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procedure. Purified epithelial cell adhesion molecule
EpCAM-positive cells from fetal and postnatal livers
have been used to generate mature hepatocytes [8], but
this marker is also expressed in the visceral endoderm
and in several progenitor cell populations and cancers,
and is associated with undifferentiated hESCs [9,10]. A
cell surface marker specific to hepatic progenitors that
could be used for the simple and efficient fluorescence-
activated cell sorting (FACS) of hepatic progenitors
differentiated from hESCs has not yet been identified.
Alternative approaches based on the use of conven-
tional lentiviral vectors (lentivectors) are complicated
by the problem of genomic integration of transgenes
and viral DNA elements, potentially precluding their use
for clinical applications. However, integrase-defective
lentivectors (IDLVs) can be produced by introducing a
mutation into the integrase gene, which specifically pre-
vents lentivector DNA integration [11]. Transduction with
IDLVs results in the generation of circular vector epi-
somes, and the transgene is expressed from these non-
integrated proviral forms, which are progressively lost in
proliferating cells, resulting in transient gene expression.
In a previous study, we designed a third-generation inte-
grating lentivector (ILV) in which the gene encoding for
green fluorescent protein (GFP) was under the control of
the human liver-specific APOA-II promoter. We previ-
ously showed that this transgene is expressed in trans-
duced primary simian hepatocytes both in vitro and
in vivo after the transplantation of these transduced cells
into animal models [12,13].
By combining 1) cell sorting using a hepatic-specific
promoter, 2) high-titer preparations of purified ILVs and
IDLVs, and 3) a specific integrase inhibitor, we created a
robust and highly efficient method for purifying hESC-
derived hepatic progenitors devoid of DNA integration.
Results
Hepatic specificity of reporter lentivector expression
We first investigated the specificity of the APOA-II pro-
moter by transducing various cell lines with APOA-II-GFP
lentivector (Figure 1A). Whereas the ubiquitous elongation
factor (EF)1α promoter was expressed in all cell lines
tested, the APOA-II promoter induced high levels of GFP
expression only in the hepatic cell line HuH7. GFP expres-
sion was not detected in the human epithelial cell lines
tested (A549, Hela, MCF7) nor in the COP cell line de-
rived from human pancreatic islet cells, which like hep-
atic cells, are of endoderm origin (Figure 1B). Because a
meso-endoderm stage is common to both mesoderm
and endoderm, we also verified the specificity of the
APOA-II promoter in endothelial cells (human umbilical
vein endothelial cells; HUVECs), primary human fibro-
blasts (Figure 1B), and primary mesenchymal stem cells(MSCs) (Figure 1D). Figure 1C shows a representative
FACS analysis of primary fibroblasts transduced with ei-
ther the elongation factor (EF)1α-GFP lentivirus or the
APOA-II-GFP lentivirus.
Undifferentiated H9 cells transduced with APOA-II-GFP
vectors at a multiplicity of infection (MOI) of 10
displayed normal hESC morphology (Figure 1E) and
karyotype (Figure 1F) and, as expected, did not express
GFP (not shown).
Purification of hepatic progenitors by FACS
To assess the suitability of the APOA-II reporter vector
for a cell-sorting strategy, we directed the differenti-
ation of transduced ES cells into hepatic progenitors
[7], and the expression of APOA-II-GFP was investi-
gated during the various stages of cell differentiation.
As expected, hepatoblasts (day 16) expressed hepatic
progenitor markers, such as α-fetoprotein (AFP),
cytokeratin 19 (CK19), hepatic nuclear factor (HNF)4α
and HNF6 (Figure 2A, B). From day 0 to day 8, early
markers of differentiation, such as sex determining re-
gion Y-box (SOX)17 and HNF4α, were sequentially
detected but less than 3% of the cells expressed GFP,
reflecting the low level of APOA-II promoter activity at
this stage (Figure 3A). On day 16 (hepatic progenitor
stage), up to 39% of the cells expressed GFP (Figure 3A, B).
Sorting at day 16 yielded a population highly enriched
in ApoA-II-GFP-expressing cells (>99%) (Figure 3B).
After sorting, GFP-positive cells were plated on type I
collagen-coated plates and maintained in culture. After
a 48-hour period, purified GFP-positive cells were
homogeneously distributed, displayed the morphology
of hepatic progenitors (Figure 3C), and expressed both
CK19 and AFP (Figure 3D).
Generation of a purified population of hepatic
progenitors devoid of virus integration
Use of a conventional lentivector would result in major
changes to the genetic material of the host genome, in-
cluding potentially harmful mutations. Therefore, we
aimed to develop a cell-purification strategy that would
prevent permanent genome modification. EF1α-GFP and
APOA-II-GFP were produced in an integration-defective
form, with a GAG/POL packaging plasmid encoding the
D64V mutant integrase [14,15].
We developed a protocol by transducing H9 cells with
EF1α-GFP-IDLV at various time points (days 8 (not
shown), 10 (not shown) and 13) of the differentiation
protocol, and monitoring the kinetics of GFP expression
from days 3 to 7 after transduction. The percentage of
GFP-positive cells was highest on day 3 after transduc-
tion (see Additional file 1: Figure S1A), with 60% of the
cells expressing GFP at an MOI of 30 when cells were
transduced on day 13 of differentiation. Therefore, for
Figure 1 (See legend on next page.)
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Figure 1 Specificity of apolipoprotein A-II (APOA-II) promoter for hepatic cells. (A) Schematic diagram of the APOA-II-green fluorescent
protein (APOA-II-GFP) lentivector. (B) Relative mean fluorescence intensity (MFI) representing GFP expression was evaluated in various types of
cells: different epithelial cell lines (A549, HeLa, MCF7), hepatoma cells (HuH7), primary fibroblasts, human umbilical vein endothelial cells (HUVECs),
and human pancreatic (COP) cells. Non-transduced control (NT, grey bars), transduced with elongation factor (EF)1α lentivector (black bars), or
with APO-AII-GFP (white bars) lentivector. (C) Fluorescence-activated cell sorting (FACS) analysis of GFP-expressing fibroblasts 3 days after
transduction with APOA-II-enhanced (e)GFP or EF1α-eGFP lentivectors. (D) Phase-contrast and fluorescence micrographs after the transduction of
mesenchymal stem cells (MSCs) with EF1α-GFP and APOA-II-GFP lentivectors. (E) Phase-contrast image of a representative H9 cell colony
transduced with APOA-II-GFP lentivector. (F) Karyotype analysis of H9 cells transduced with APOA-II-GFP lentivector.
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on day 13 and sorted the fluorescent cell population 3
days later, that is, on day 16 of differentiation. Cells
were transduced with purified EF1α-GFP-ILV and EF1α-
GFP-IDLV to confirm the advantages of IDLV over ILV
for sorting.
On day 3 after transduction, the proportions of GFP-
IDLV cells and GFP-ILV cells were similar, owing to epi-
some transcription (see Additional file 1: Figure S1B).
However, the proportion of GFP-IDLV cells subsequently
decreased to 1% 14 days after transduction, whereas the
proportion of GFP-ILV-positive cells remained stable
(approximately 50%) as expected (see Additional file 1:
Figure S1B).
We also investigated the benefits of using raltegravir, an
integrase inhibitor used in the clinical treatment of HIV
infection, during the transduction protocol to prevent any
residual vector integration [16]. Addition of raltegravir
had no effect on the percentages of GFP cells on day 3
after transduction for either type of vector, owing to theFigure 2 Expression of specific markers by human embryonic stem cell
picture of four separate experiments showing transcript levels of hepatic cell
immunofluorescence staining for human GATA binding protein (GATA)4, hep
cytokeratin (CK)19, hepatic nuclear factor (HNF)4α , and HNF6.presence of non-integrated forms, suggesting that this
inhibitor has no effect on differentiation and/or trans-
duction efficacy. On day 14 after transduction, the pro-
portion of IDLV-transduced GFP-positive cells had
decreased to less than 1%, in the presence or absence of
raltegravir. By contrast, raltegravir decreased the fraction
of GFP-ILV-positive cells to less than 1% (see Additional
file 1: Figure S1B).
The final protocol used for the purification of hepatic
progenitors from hESCs is depicted in Figure 4A. As
reported for APOA-II-GFP-ILV, about 39% of differenti-
ated cells were positive for APOA-II-GFP-IDLV at the
time of sorting (Figure 4B). After a 2-day culture period,
quantitative reverse transcription-(RT)-PCR of GFP-
sorted cells confirmed enrichment of CK19 expression
compared with qRT-PCR performed on the day of
sorting (Figure 4C). Several co-immunostaining experi-
ments showed that these cells co-expressed CK19 and
AFP, although at different levels, confirming their hep-
atic progenitor phenotype (Figure 4D).s (hESCs) differentiating to hepatic progenitors. (A) Representative
markers on D8 and D16 of differentiation. (B) Representative
atic nuclear factor (HNF)3β, epithelial cell adhesion molecule (EpCAM),
Figure 3 (See legend on next page.)
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Figure 3 Purification of hepatic progenitors upon differentiation of human embryonic stem cells (hESCs) transduced with
apolipoprotein A-II-green fluorescent protein (APOA-II-GFP) lentivectors. (A) Immunofluorescence staining showing expression of cell
markers characteristic of hESCs (day 0; octamer-binding transcription factor (OCT)4), endoderm (day 3; sex determining region Y-box (SOX)17),
hepatic endoderm (day 8; hepatic nuclear factor (HNF)4α), hepatic progenitors (day 16; α-fetoprotein (AFP) and representative fluorescence-activated
cell sorting (FACS) analysis of the same cells showing time course of GFP expression after transduction of hESCs with APO-AII-GFP-integrating
lentivector (ILV) (green lines) versus non-transduced cells (black lines). (B) Representative GFP fluorescence profile on day 16 of differentiation, before
and after FACS. Left panel: GFP-positive cells of the low/right quadrant, representing 39% of the living cells, were sorted and subsequently analyzed, as
illustrated in the right panel, where 99% were GFP-positive. (C) Phase-contrast images of sorted hESC-derived hepatic progenitors, 48 hours after
plating. (D) Representative fields of immunofluorescence staining of sorted hepatic progenitor cells treated with α-fetoprotein (AFP) (green) and
cytokeratin (CK)19 (red) antibodies.
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viral DNA integration
After sorting, cells were allowed to reach confluence in a
serum-free medium previously defined for the culture of
fetal hepatic progenitors, and then they were cultured in
hepatocyte culture medium supplemented with hepato-
cyte growth factor (HGF) and Oncostatin M. On day 18
after sorting (day 34 of differentiation), we analyzed the
GFP expression of the cells. Only a very small number
of fluorescent cells were visible by fluorescence micros-
copy, and FACS analysis confirmed that no more than
0.1% of the cells were fluorescent, whereas at day 16
(3 days after transduction) up to 35% cells were trans-
duced (Figure 5A).
Cells transduced with either ILV or IDLV in the pres-
ence or absence of raltegravir were analyzed or passaged
on day 16 of differentiation (day 3 after transduction),
and the presence of lentivector DNA forms were ana-
lyzed using the described probe (see Additional file 2:
Figure S2). A band common to both integrated and two
bands (ECOR1) specific for non integrated forms (one
and two long terminal repeat (LTR) circle of the
lentivector DNA were detected in all transduced cells
(Figure 5B). At day 14 after transduction (day 27 of dif-
ferentiation), lentivector DNA could be detected only in
cells transduced with ILV in the absence of raltegravir
(Figure 5B). Integrated viral DNA was absent from cells
transduced either with IDLV or with IDLV or ILV in the
presence of raltegravir. In purified cells at day 30 of dif-
ferentiation (day 14 of culture), no integrated or episomal
DNA derived from lentivectors was detected (Figure 5B).
qPCR of genomic DNA confirmed the absence of viral
DNA from all samples on day 27 of differentiation, with
the exception of cells transduced with ILV in the absence
of raltegravir (Figure 5C). The threshold of detection was
analyzed by qPCR using a clonal cell line control
(HCT116) which, after transduction with a GFP lentivirus,
contained one lentiviral integration per cell (see Add-
itional file 3: Figure S3). At a dilution of 1 in 2,000, inte-
gration of viral DNA was 10 times higher than the
background in control non-transduced cells, and it was 7
to 7.5 time higher at dilutions of 1 in 4,000, 1 in 5,000,and 1 in 10,000. Thus, these studies established the limit
of detection of an integration event of less than 1 in
10,000.
We then investigated whether hepatic progenitors
were able to differentiate further into more mature he-
patocytes. On day 16 after sorting (day 32 of differenti-
ation), the human progenitor-derived hepatocytes had
acquired a morphology resembling that of hepatocytes
(Figure 5D), and had the functional characteristics of
mature human hepatocytes. These cells could incorpor-
ate and export indocyanin green (ICG) (Figure 5E, F),
secrete albumin (Figure 5G), express clotting Factor IX
(FIX) mRNA (Figure 5H), and store glycogen (Figure 5I).
Finally, to further evaluate the functionality of differ-
entiating hepatocytes, we sought to visualize expression
of the mature hepatocyte-specific cytochrome P450 3A4
(CYP3A4). The cells were transduced on day 25 of differ-
entiation (day 9 after sorting) with a lentivector expressing
GFP under the control of the CYP3A4 promoter, and ana-
lyzed for fluorescence on day 33 (Figure 6A) [17]. Treat-
ment of transduced cells with rifampicin, an inducer of
CYP3A4, produced a modest increase in GFP-positive
cells, both in proportion and in mean fluorescence inten-
sity (MFI) suggesting that the CYP3A4 promoter is indeed
regulated in these hepatocytes (Figure 6B, C).
Discussion
Safe and efficient methods for the purification of pro-
genitor cells are a prerequisite to allow use of differenti-
ated hPSCs for regenerative medicine in order to
minimize risks of tumorigenesis in patients. To date,
strategies for purifying a given cell population have used
either a cell surface protein specific for the target cell
population, such as stage-specific embryonic antigen
(SSEA)-1 for isolation of human multipotent cardiovas-
cular progenitor cells [18], or lentivectors expressing a
reporter gene under the control of a specific promoter
[19]. In this study, we show for the first time that it is
feasible to purify a population of hESC-derived hepatic
progenitors that are devoid of viral integration and that
can differentiate further into more mature hepatocyte-
like cells. Our strategy was to engineer human hepatic
Figure 4 (See legend on next page.)
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Figure 4 Purification of hepatic progenitors after transduction with integrase-defective apolipoprotein A-II-green fluorescent protein
(APOA-II-GFP) lentivectors. (A) Flowchart summarizing protocol for purification of hepatic progenitor cells. (B) Representative GFP fluorescence
analyses of the cell population carried out on at day 16 (3 days after transduction on day 13 of differentiation with the APOA-II-GFP integrase-
defective lentivector (IDLV) by immunofluorescence microscopy (left panel) and fluorescence-activated cell sorting (FACS) analysis (right panel).
(C) Cytokeratin (CK)19 transcript levels in hepatic progenitors were determined immediately before and after sorting (day 13 and 16 of
differentiation, respectively) by quantitative reverse transcription (qRT)-PCR analysis. (D). A phase-contrast image of human embryonic stem cells
(hESC)-derived hepatic progenitors plated on type I collagen and cultured for 48 hours after sorting (magnification × 100). Immunofluorescence
staining of representative fields of sorted hepatic cells treated with α-fetoprotein (AFP) (green) and CK19 (red) antibodies after 48 hours of culture
on type 1 collagen.
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express GFP under the control of liver-specific APOA-II.
It was crucial to choose appropriate vectors that would
exhibit high transduction efficiency at low MOI and
would result in a vector-free enriched cell population.
For this study, we developed a method for producing
purified ILVs and IDLVs at high titers in order to
minimize any deleterious effects upon transduction of
target cells [20]. The APOA-II gene is expressed in liver
and intestine, and we previously constructed a
lentivector in which we inserted APOA-II regulatory se-
quences to drive GFP expression, and confirmed its
functionality both in vitro and in vivo [12,13]. In the
current study, to assess the specificity of our construct,
various cell types were transduced, including human epi-
thelial lines and different sources of mesoderm, such as
primary human MSCs and fibroblasts. When driven by
the APOA-II promoter, GFP was highly expressed only in
hepatoma cells, confirming the suitability of this tool for
purification of progenitors of the hepatic lineage and not
for cells from mesodermal origin. Of note, GFP was not
expressed in transduced human primary fibroblasts. Bi-
potent mesendoderm, which can give rise to both defini-
tive endoderm and mesoderm lineages, and transient pop-
ulations expressing markers of both lineages, have been
visualized in vivo [21,22].
The weak GFP expression seen in a low percentage of
differentiating hES cells increased during the differenti-
ation protocol, confirming the progressive differentiation
of endoderm cells into hepatic cells. This was confirmed
by the upregulation of HNF4α, a key hepatic transcrip-
tion factor in hepatic progenitors [23]. Thus, our results
showed that the cells generated in our culture system
display the physiological regulation of a hepatic-specific
promoter and also display markers of hepatoblasts. Such
markers were first identified in developing mouse liver
[24], and their expression in human progenitors has
been confirmed by several groups, including us [25,26].
Our results also show that our purification approach
does not prevent the sorted hepatoblasts from differenti-
ating further into more mature hepatocytes, able to ex-
press FIX (a clotting factor specific to hepatocytes),export ICG, secrete albumin, and express and regulate
the CYP3A4 promoter. The hepatocytes we generated
were not as fully mature as adult hepatocytes, but to our
knowledge, this stage has not yet been achieved with
pluripotent stem cell-derived hepatocytes [27].
HIV integrase catalyses the enzymatic reactions that
result in the covalent integration of the viral DNA into
the host DNA [28]. HIV-1 reporter viruses harboring
mutations of integrase active-site residues are unable to
catalysz viral DNA integration, but still yield a reprodu-
cible level of reporter gene expression from the non-
integrated proviral forms via DNA episomal forms.
These viral episomes are progressively lost in dividing
cells, leaving only the background level associated with
non-specific random integration. Two types of circular
episomes with intact coding regions are also produced.
Homologous recombination within the LTRs generates a
circular episome with a single LTR (1-LTR circle). Non-
homologous end joining of the linear episome results in
a circular episome with two adjacent LTRs.
Our results show that, 17 days after progenitor trans-
duction, lentivector integration was undetectable. These
results are in agreement with those of Mátrai et al., who
infused IDLVs into liver and provided molecular evi-
dence that the background integration was not mediated
by residual catalytic activity of the mutant integrase [29].
Inhibition of integration by specific integrase inhibitors
irreversibly blocks HIV-1 replication. We reasoned that,
as an alternative to IDLV, use of an HIV integrase inhibi-
tor in combination with ILV should also prevent any in-
tegration events. Raltegravir, which specifically targets
the strand transfer reaction, and is currently being used
in clinical trials [30], abolished vector integration in our
ILV-transduced progenitors, showing that use of ILV in
combination with HIV integrase inhibitor can be an al-
ternative to IDLV. Thus, our methods can be used to
purify hepatic progenitors prior to their differentiation
into hepatocytes, and offers the advantage that resulting
cells are free of lentivector DNA integration. Given that
xenogenic reagents such as mouse embryonic fibroblasts
(MEFs) or Matrigel (BD Biosciences) are incompatible
with the use of hPSCs to treat debilitating human
Figure 5 (See legend on next page.)
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Figure 5 Differentiation of hepatoblasts into hepatocyte-like cells free of vector integration. (A) Fluorescence microscopy (left panel) 18
days after sorting and fluorescence-activated cell sorting (FACS) analysis of green fluorescent protein (GFP) expression from (left) non-transduced
progenitors (left FACS panel), and transduced progenitors (middle) 3 days after transduction and (right) and 18 days after sorting. The numbers
indicate the percentages of GFP-positive cells in the analyzed P15 gate. (B) Representative Southern blots of integrated and non-integrated forms
(1-long terminal repeat (LTR) and 2-LTR circles) of the lentivector at 3 days and 14 days after transduction (days 16 and 27, respectively, of
differentiation) in the presence or absence of raltegravir. (C) Total copy number of lentivectors was analyzed in the same cells as in (B) by
quantitative-(q)PC). (D) Representative phase-contrast image of differentiating purified hepatic progenitors on day 14 after sorting. (E, F) Uptake
and excretion of indocyanin green. (G) Albumin secretion of undifferentiated H9 cells, non-purified hepatic cells, purified hepatic cells and Hepa-
RG hepatoma cell line in the culture medium was evaluated by ELISA. (H) Representative transcript levels of hepatocyte-specific clotting Factor IX
(FIX) on days 16, 25, and 35 of differentiation. (I) Glycogen storage of the purified cells was assessed by periodic acid-schiff (PAS) staining, 14 days
after sorting (day 30 of differentiation).
Figure 6 Expression of green fluorescent protein (GFP) driven by the cytochrome P450 3A4 (CYP3A4) promoter in purified hepatocyte-
like cells. (A) Fluorescence microscopy of GFP-expressing cells on day 33 after transduction (day 25 of differentiation; day 9 after sorting) by a
lentivector expressing GFP under the control of CYP3A4 promoter. (B) Fluorescence-activated cell sorting (FACS) analysis of GFP expression on
day 33 of differentiation from non-transduced cells and from cells transduced on day 25 and treated ont day 30 for 72 hours with vehicle
(DMSO) alone or with rifampicin. (C) Quantification of analysis in gate P4 (B) by the CFlow software (Accuri Flow Cytometer; BD Biosciences, Le
Pont-de-Claix, France).
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ment of synthetic matrices, should facilitate the develop-
ment of protocols for the generation of mature
hepatocytes for future clinical applications.
Conclusions
Our approach, based on purified IDLV, facilitates the
generation of a population of purified hESC-derived
hepatic progenitors, which are devoid of integrated viral
DNA, and can be subsequently differentiated to mature
hepatocyte-like cells. This method represents a techno-
logical advance for many areas of research because it
can be adapted easily for the purification of stem cell-
derived populations such as pancreatic or neuronal cells
for therapeutic purposes and also for in vitro applica-
tions such as drug screening.
Methods
Cell culture
Human H9 embryonic stem cells (WA09, WiCell, Madison,
WI, USA) were cultured on MEFs treated with mito-
mycin C. Cells were manually dissected and plated
onto 0.1% gelatin-coated culture dishes (Costar, Corning
Life Sciences, Acton, MA, USA) for amplification. The
human ES cell culture medium was composed of stand-
ard Dulbecco’s modified Eagle’s medium (DMEM)/F12
supplemented with 20% Knockout Serum Replacement
(Gibco/Life Technologies Corp., Saint Aubain 91190,
France), 4 ng/ml human recombinant basic fibroblast
growth factor (bFGF; R&D Systems Inc., Minneapolis,
MN, USA), 0.1 mmol/l β-mercaptoethanol, 1 mmol/l
L-glutamine, and 1% non-essential amino acids. Fetal
livers were obtained from pregnancies terminated at 11
to 13 weeks of gestation, after obtaining the informed
consent of the mothers, as recommended by the
French Ethics Committee and the local Ethics Com-
mittee of Paris XI University (Paris, France). Human
hepatoblasts were then isolated and cultured as previ-
ously described [25,32]. Primary human adult hepato-
cytes were isolated from normal liver tissue biopsy
specimens obtained during resections (partial hepatec-
tomies) for hepatic or metastatic tumors, after in-
formed consent had been obtained from the patient.
MSCs, HeLa cells, human cervical epithelial tumor
cells, HuH7cells (a human hepatoma cell line), and COP
cells (a cell line generated from SV40 transformation of
human pancreatic islets) were used to seed a six-well
microplate (CellBind; Corning Life Sciences) containing
DMEM (PAA Laboratories, Les Mureaux, France)
supplemented with 10% fetal bovine serum (FBS). They
were cultured at 37°C for 24 hours, under an atmosphere
containing 5% CO2. Transduction was performed over-
night at an MOI of 40 for MSCs and HeLa cells, and at an
MOI of 30 for HuH7 cells, in the presence of 8 μg/mlhexadimethrine bromide (Polybrene; Sigma-Aldrich
Chimie, Lyon, France). The supernatant was then replaced
with fresh culture medium.
A549 cells (a human alveolar epithelial cell line) were
used to seed six-well microplates (CellBind; Corning
Life Sciences) containing HamF12 (PAA Laboratories)
supplemented with 10% FBS, and then cultured at 37°C
for 24 hours, under an atmosphere containing 5% CO2.
Cells were transduced overnight at an MOI of 40, in
the presence of 8 μg/ml hexadimethrine bromide
(Polybrene; Sigma-Aldrich). The supernatant was then
replaced with fresh culture medium.
MCF7 cells (a breast cancer epithelial cell line) were used
to seed six-well microplates (CellBind; Corning Life Sci-
ences) containing MEM (PAA Laboratories) supplemented
with 10% FBS + 0.01 mg/ml bovine insulin (Sigma-Aldrich)
and were cultured at 37°C for 24 hours, under an at-
mosphere containing 5% CO2. Cells were transduced
overnight at an MOI of 80, in the presence of 8 μg/ml
hexadimethrine bromide (Polybrene; Sigma-Aldrich).
The supernatant was then replaced with fresh culture
medium. At 1 week after transduction, GFP expression
was analyzed by flow cytometry or fluorescence micros-
copy. Phase-contrast images were taken under a micro-
scope (Eclipse; Nikon, Tokyo, Japan).
Human fibroblasts were cultured in DMEM medium
supplemented with 10% FBS and antibiotics. HUVECs
were cultured in chemically defined EBM2 endothelial
basal medium with antibiotics. Cells were transduced
overnight at an MOI of 30. At 4 days after transduction,
GFP expression was analyzed by flow cytometry. COP
cells were cultured in low-glucose DMEM supplemented
with 10% FBS and antibiotics.
Differentiation of hESCs into hepatic progenitor cells
At 1 day before the passage of hESCs for differentiation,
30 × 60 mm cell culture dishes (CLS430166-500EA;
Corning Life Sciences) were coated with 0.1% gelatin
from porcine skin type A (61890-100G; Sigma-Aldrich).
After 90 min of incubation at room temperature, the
gelatin was removed, and dishes were washed once with
phosphate-buffered saline (PBS). A coating medium
(DMEM, 10% FBS, 100 × MEM non-essential amino
acid solution, 1% L-glutamine) was added to plates,
which were then incubated for 24 hours at 37°C, under
an atmosphere containing 5% CO2. The following day,
hESCs were dissected from MEFs. For this, the hESC cul-
ture medium was removed from the cells and replaced
with chemically defined medium (CDM) supplemented
with bovine serum albumin (BSA; Europabioproducts,
Ely, UK; 5 mg/ml final concentration), fibroblast
growth factor (FGF)2 (12 ng/ml final concentration)
and activin A (10 ng/ml final concentration). About 80
colonies of hESCs on MEFs per 60 mm dish were
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was removed from the gelatin-coated dishes, which
were washed once with 1 × PBS, then CDM-BSA
containing the previously dissected hESC clusters was
added to the plates. We used 40 dissected colonies per
pre-coated plate. After incubation for 48 hours, the
CDM-BSA was removed and replaced with CDM
supplemented with polyvinylalcohol (PVA; Sigma-
Aldrich; 1 mg/ml final concentration: CDM-PVA), activin
A (100 ng/ml final concentration), FGF2 (20 ng/ml final
concentration), bone morphogenetic protein (BMP)4
(10 ng/ml final concentration), and LY294002 (10
μmol/l final concentration). The medium was replaced
daily. After 3 days, cells were incubated with CDM-
PVA supplemented with FGF10 (50 ng/ml) for a further
3 days. Retinoic acid (0.1 μmol/l final concentration)
and SB431542 (10 μmol/l final concentration) were
then added, together with FGF10, and the cells incubated
for an additional 2 days. Finally, cells were incubated for 4
days with CDM-PVA supplemented with hydrocortisone
(1 μmol/l final concentration), FGF4 (30 ng/ml final con-
centration), HGF (50 ng/ml final concentration) and epi-
dermal growth factor (EGF; 50 ng/ml final concentration).
On day 16 of differentiation, attached cells were re-
moved in a cell dissociation buffer (0.1 mg/ml EDTA
and 0.5 mg/ml BSA in PBS), and GFP-expressing cells
were purified with a cell sorter (FACS DiVa Flow
Cytometer; Becton Dickinson, Franklin Lakes, NJ, USA).
Purified hepatic progenitors in a plating medium
(DMEM/HAM F-12, 10% heat-inactivated FBS, 1 g/l hu-
man BSA fraction V, 1% L-glutamine) were plated onto
a type I collagen-coated plate and incubated for 4 hours.
Cells were then incubated overnight with hepatic pro-
genitor medium (HPM: DMEM/HAM F-12/Williams
Medium E 1:1, 0.24% linoleic acid-albumin 2:1, 5.10-8
mol/l triiodo-L-thyronine, 0.2 IU insulin, 10-6 mol/l
hydrocortisone, 6 × 10-4 mol/l vitamin C, 6 × 10-4 mol/l hu-
man apo-transferrin) supplemented with HGF (50 ng/ml).
For the next 2 days, cells were incubated with HPM
supplemented with HGF (50 ng/ml) and EGF (20 ng/ml).
Cells were then incubated with hepatocyte culture medium
(Lonza Group Ltd, Basel, Switzerland) supplemented with
the associated kit (HCM Bullet Kit; Lonza) and Oncostatin
M (10 ng/ml). Phase-contrast images were taken under a
microscope (Eclipse; Nikon).
Lentivector production
The APOA-II promoter was previously cloned in
lentivectors by our laboratory [12]. The EF1α-GFP and
APOA-II-GFP cassettes were inserted into third-
generation self-inactivating (SIN) lentivectors containing
a WPRE sequence and a mutated GAG sequence. These
vectors were designed and produced by Vectalys SAS
(Toulouse, France).Viral vectors were produced in a human embryonic
kidney (HEK)293T cell line. The HEK293T cells were
used to seed a 10-layer cell culture chamber (6320 cm2;
CellSTACK; Corning Life Sciences) and were transfected
2 days later, in fresh DMEM without fetal calf serum
(FCS) supplemented with 1% penicillin/streptomycin
and 1% ultraglutamine (PAA Laboratories). Cells were
simultaneously transfected with three plasmids: pVSVG,
pGagPol, and pLV-APOA-II-GFP. The supernatant was
discarded 24 hours after transfection, and replaced with
fresh non-supplemented DMEM. The harvested vectors
were clarified by centrifugation for 5 minutes at 3000 g,
followed by microfiltration through a sterile filter unit
with 0.45 μm pores (Stericup; Millipore Corp., Billerica,
MA, USA). The crude vector preparation was concen-
trated and purified by tangential flow ultrafiltration, and
the supernatant was then diafiltered against DMEM.
Once the diafiltration was complete, the retentate was
recovered, and further concentrated by ultrafiltration.
Quantification of functional particle by FACS
HCT116 cells were used to seed 96-well plates at a dens-
ity of 12,500 cells per well, in 250 μl of DMEM
supplemented with 10% FCS, 1% penicillin/streptomycin,
and 1% ultraglutamine (complete medium). Five serial
dilutions with complete medium were performed 24 hours
later for each vector sample and an rLV-EF1-GFP internal
standard. The cells were transduced with these serial dilu-
tions in the presence of 8 μg/ml hexadimethrine bromide
(Polybrene; Sigma-Aldrich). For each sample series, one
well of non-transduced cells was included as a control. At
4 days after transduction, the cells were released by tryp-
sin treatment and harvested by centrifugation, then each
cell pellet was resuspended in 250 μl of PBS. The titer was
calculated by determining the number of transducing
units (TU)/ml by FACS.
Quantification of physical particles by p24 ELISA
The p24 core antigen was detected directly in the viral
supernatant with a HIV-1 p24 ELISA kit (Perkin Elmer,
Waltham, MA, USA) in accordance with the manufac-
turer’s instructions. The absorbance of each microplate
well was determined with a microplate reader, and cali-
brated against tan HIV-1 p24 antigen standard curve.
The viral titer, expressed in physical particles per ml,
was calculated from the amount of p24, assuming that
1 pg of p24 corresponds to 104 physical particles.
Transduction of hESCs by lentivectors
Before transduction, hESCs were manually dissociated
and incubated, in clumps, with viral particles for 2 hours
at 37°C in low-attachment 24-well plates (Corning Life
Sciences), with gentle rocking. They were then added to
MEFs in hESC medium. The undifferentiated transduced
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[12] devoid of serum and supplemented with insulin,
transferrin, and defined lipids, to which was added BSA
(5 mg/ml fraction V; Europabioproducts) for expansion
or PVA (1 mg/ml, mean molecular weight 30,000 to
70;000; P8136-250G, Sigma) as a substitute for BSA.
Transduction of human ESC-derived hepatic progenitor
cells by IDLV
On day 13 of differentiation, cells were washed once
with PBS, and fresh CDM-PVA supplemented with HGF
(50 ng/ml final concentration), EGF (50 ng/ml final con-
centration), FGF4 (30 ng/ml final concentration), and
hydrocortisone (10-6 mol/l final concentration) were
added. The IDLV was used at an MOI of 30 and was in-
cubated with cells for 24 hours. The cells were cultured
for a further 2 further days, with the medium changed
daily. The HIV integrase inhibitor raltegravir was added
to the culture medium on the day of transduction, at a
concentration of 1 μmol/l, and was maintained in the
medium for 24 hours.
Cell preparation for sorting and plating
Differentiated cells were washed with PBS and incubated
for 5 min at 37°C with 2 ml per 60 mm dish of cell dis-
sociation buffer (0.01 mg/ml EDTA, 0.05 mg/ml BSA in
PBS without Ca2+/Mg2+, pH 7.5). Dissociated cells were
suspended in 5 ml of plating medium (DMEM/F12; 20%
human serum, PAA Laboratories), and separated by cen-
trifugation for 5 minutes at 400 g. The cell pellet was fi-
nally suspended in plating medium (DMEM/F12, 20%
human serum 1 mmol/l L-glutamine, 100 μl/ml antibiotics)
supplemented with HGF (50 ng/ml final concentration), atTable 1 Primer sequences used for reverse transcription-PCR
Gene Direction Primer sequence 5′→3′
FoxM1B Forward GGGCGCACGGCGGAAGATGAA
Reverse CCACTCTTCCAAGGGAGGGCTC











Reverse TCTCCTTCTGCATCCTGTCGa density of 3 × 106 cells/ml for FACS. GFP-positive cells
were plated onto a 24-well type I collagen-coated plate
(BD Biosciences) at a density of 2 × 105 cells per well.
At 4 hours after plating, the medium was replaced with
CDM-PVA supplemented with HGF (50 ng/ml final
concentration), EGF (50 ng/ml final concentration),
and FGF4 (30 ng/ml final concentration), and cells were
cultured for a further 2 days before analysis. Phase-
contrast image were taken under a microscope (Eclipse;
Nikon).Southern blotting
Southern blot hybridization was carried out using
digoxigenin (DIG System; Roche Applied Science, Basel,
Switzerland) in accordance with the manufacturer’s
protocol. Briefly, 5 μg of genomic DNA from each sam-
ple was digested with either EcoRI (New England
Biolabs, Beverly, MA, USA) for the detection of 1- and
2-LTR circular DNA (4,396 bp and 4,627 bp bands, re-
spectively) or with EcoRI and BamHI (New England
Biolabs) for the detection of total lentiviral DNA as a
1,403 bp band. The digested DNA was subjected to elec-
trophoresis in a 1% agarose gel. Gels were blotted onto
Hybond-N + membrane (Millipore) overnight in 20 × SSC
buffer (Sigma-Aldrich). As a probe, we used 1.3 kb PCR
(GFP-WPRE) fragments (see Additional file 1: Figure S1B)
labeled with DIG-11-dUTP (PCR DIG Probe Synthesis
Kit; Roche). The probe was hybridized with the membrane
overnight at 42°C (DIG Easy Hyb solution; Roche), and
the probe detected ()DIG Detection System; Roche).
The DIG-labeled probe was detected with an anti-
digoxigenin-AP Fab fragment (Roche) and visualized
with achemiluminescent substrate (CSPD; Roche).in this study








Table 3 Antibodies used in this study
Antibody Company Reference number Dilution
Primary
EpCam AbCys abc171 1:20
CK19 Dakoa M0888 1:50
AFP Dako N1501 1:300
HNF4α Santa Cruzb SC-8987 1:100
E-cadherin Dako M3612 1:100
SOX17 R&D MAB1924 1:100
OCT4 Santa Cruz SC-5279 1:200
NANOG R&D AF1997 1:100
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The copy number of the lentiviral vector was deter-
mined by qPCR analysis. The qPCR experiments were
performed with 150 ng of total DNA, SYBR GreenER
(Invitrogen Corp., Carlsbad, CA, USA), specific primers
binding to the WPRE sequence, and albumin (house-
keeping gene) in a final volume of 20 μl (Step One Real-
Time PCR System; Applied Biosystems, Foster City, CA,
USA). Copy number was calculated by referring the Ct
values for each sample to a standard plasmid curve. All
qPCRs were performed in duplicate.
To determine the limits of detection of residual
lentivector integration, serial dilutions were performed
using genomic DNA from a clonal cell line containing
only one copy of ILV. The line was established by trans-
duction of HCT116 cells with a GFP-expressing ILV,
followed by clonal selection, and the copy number was
quantified by Southern blotting. Serial dilutions of gen-
omic DNA bearing one copy per cell were performed by
two-fold dilutions in genomic DNA from control non-
transduced HCT116 cells. A range of dilutions from 1:2
to 1:10000 were tested. All qPCRs were performed in
duplicate.
RT-PCR
Total RNA was extracted (RNeasy Mini Kit (Qiagen
Inc., Valencia, CA, USA) from hESCs, differentiated hep-
atic progenitors, and human fetal and adult hepatocytes,
following the manufacturer’s protocol. For each sample,
0.6 μg of total RNA was reverse-transcribed with reverse
transcriptase (Superscript II; Invitrogen), and amplifica-
tion by PCR was performed (PCR Nucleotide Mix Kit;
Promega, Charbonnières, France). The primers used and
the sizes of the amplicons obtained are described in
Table 1.
PCR and real-time qPCR
Real-time PCR mixtures were prepared (SensiMiX Kit;
Bioline, Paris, France), in accordance with the manufac-
turer’s instructions. Primers used for real-time PCR ana-
lyses are shown in Table 2. The DNA was then
denatured at 95°C for 10 minutes, and subjected to 40 cy-
cles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C
for 30 seconds, followed by a final extension at 72°C for
10 minutes. Real-time PCR was performed in a real-timeTable 2 Quantitative PCR primer sequences used in this
study




Reverse TGCCTGACCAAGGAAAGCPCR system (model 7300 Applied Biosystems), in trip-
licate, with normalization to hypoxanthine-guanine
phosphoribosyltransferase (hPRT) levels in the same
run. The real-time qPCR results are presented as the
means of three independent experiments; error bars
indicate the SEM.
FACS analysis of sorted cells
After transduction with the IDLV ApoA-II-GFP
lentivector, the differentiating hepatocytes were analyzed
for GFP expression 14 days after progenitor sorting,
using a cytometer (n Accuri C6; Becton Dickinson) and
associated software (CFlowPlus; Becton Dickinson).
Transduction of purified progenitors
Purified progenitors were transduced 5 days after sorting,
with the Cyp3A4-GFP lentivector (kindly provided by Dr
Anne Corlu, INSERM U 991), and fluorescence was
assessed 12 days later. Rifampicin (10 μmol/l) or DMSO
was added to the plates at day 30 for 48 hours, and cells
were analyzed 1 day later (day 33).
Immunocytochemistry
Cells were fixed by incubation with 4% paraformalde-
hyde for 10 minutes at room temperature, then washed
with 50 mmol/l NH4Cl in PBS for 10 minutes, and
permeabilized by incubation with 0.1% Triton X-100 for
4 minutes. Cells were blocked by incubation with 3%
serum in PBS for 1 hour. Primary antibodies were di-
luted in PBS supplemented with 4% BSA (see Table 3 for
the corresponding dilution) and incubated with cells forSSEA 4 AbCys VMA 4304 1:100
TRA 1-60 Millipore MAB4360 1:100
Secondary
Goat anti-mouse Molecular Probesc A21123 1:800
Chicken anti-goat Invitrogen A21467 1:800
Goat anti-rabbit Molecular Probes A11010 1:800
aDako, Glostrup, Denmark.
bSanta Cruz Biotechnology Inc., Santa Cruz, CA, USA.
cMolecular Probes, Eugene, OR, USA.
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with PBS and incubated with secondary antibodies diluted
in PBS supplemented with 4% BSA (see Table 3 for corre-
sponding dilution) for 1 hour at room temperature. Cell
nuclei were stained with 4',6-diamidino-2-phenylindole
(DAPI), and cells were mounted in (Vectashield
Mounting Medium; Vector Laboratories/AbCys, Paris,
France). Fluorescence micrographs were obtained with
AxioVision Rel. 4.8 microscopy software.
ICG uptake and release
The ICG uptake test was performed on cells 17 days
after sorting, by incubating the cells with 1 mg/ml ICG
for 60 min at 37°C. Cells were then washed in medium,
and ICG release was evaluated 16 hours later.
Albumin secretion
Albumin concentrations in cell culture medium were
measured with a kit specific for human albumin detec-
tion, in accordance with the manufacturer’s instructions
(Dade Behring SAS, France) in the Department of Bio-
chemistry, Bicêtre Hospital.
Glycogen storage was assayed by the periodic acid-
Schiff technique according to McManus [33].
Additional files
Additional file 1: Figure S1. Transient green fluorescent protein (GFP)
expression after transduction of human embryonic stem cells (hESCs)
with elongation factor (EF)1α-GFP integrase-defective lentivectors (IDLVs).
(A) Time course of fluorescence-activated cell sorting (FACS) analysis
used to analyze fractions of fluorescent GFP-expressing cells after
transduction of H9 cells with EF1α-GFP-IDLV at a multiplicity of infection
(MOI) of 10 and 30. (B) Time course of FACS analysis showing similar
proportions of GFP-IDLV cells and GFP-integrating lentivectors (ILV) cells 3
days after transduction, and a decrease in the proportion of GFP-IDLV
cells 10 and 14 days after transduction, and of EF1α-GFP-ILV cells in the
presence of raltegravir.
Additional file 2: Figure S2. (A) Genetic map of 1-long terminal repeat
(LTR) and 2-LTR circular DNA. (B) Map of the probe used for the Southern
blotting experiments. After double BamHI/EcoRI digestion, a 1,316 bp
band common to integrated and non-integrated forms of the lentivector
DNA was detected. After single EcoRI digestion, only non-integrated
forms (1-LTR and 2-LTR circle) of the lentivector DNA were detected.
Additional file 3: Figure S3. Limits of detection of virus copy number.
Serial dilutions (1:50 to 1:10000) of genomic DNA from a clonal cell line
containing one copy number of an integrating green fluorescent protein
(GFP)-expressing lentivirus (D2) and derived from HCT 116 cekks. HCT 116
NT: control non-transduced cells.
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